Kim De Veirman

Prof. Kim De Veirman

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2016 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
JWJinheng Wang
Jinheng Wang
KVKim De Veirman
Kim De Veirman
SFSylvia Faict
Sylvia Faict
MFMaria Antonia Frassanito
Maria Antonia Frassanito
DRDomenico Ribatti
Domenico Ribatti
Eline MenuEline Menu
Eline Menu

2 November 2015 in Oncotarget
Verified
Journal Article
Open access
JWJinheng Wang
Jinheng Wang
KVKim De Veirman
Kim De Veirman
NBNathan De Beule
Nathan De Beule
KMKen Maes
Ken Maes
EBElke De Bruyne
Elke De Bruyne
Eline MenuEline Menu
Eline Menu
The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells

8 November 2018 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
SFSylvia Faict
Sylvia Faict
JMJoséphine Muller
Joséphine Muller
KVKim De Veirman
Kim De Veirman
EBElke De Bruyne
Elke De Bruyne
KMKen Maes
Ken Maes
Eline MenuEline Menu
Eline Menu
Progression of multiple myeloma (MM) is largely dependent on the bone marrow (BM) microenvironment wherein communication through different factors including extracellular vesicles takes place. This cross-talk not only leads to drug resistance but also to the development of osteolysis. Targeting vesicle secretion could therefore simultaneously ameliorate drug response and bone disease. In this paper, we examined the effects of MM exosomes on different aspects of osteolysis using the 5TGM1 murine model. We found that 5TGM1 sEVs, or ‘exosomes’, not only enhanced osteoclast activity, they also blocked osteoblast differentiation and functionality in vitro. Mechanistically, we could demonstrate that transfer of DKK-1 led to a reduction in Runx2, Osterix, and Collagen 1A1 in osteoblasts. In vivo, we uncovered that 5TGM1 exosomes could induce osteolysis in a similar pattern as the MM cells themselves. Blocking exosome secretion using the sphingomyelinase inhibitor GW4869 not only increased cortical bone volume, but also it sensitized the myeloma cells to bortezomib, leading to a strong anti-tumor response when GW4869 and bortezomib were combined. Altogether, our results indicate an important role for exosomes in the BM microenvironment and suggest a novel therapeutic target for anti-myeloma therapy.

4 July 2019 in Blood
Verified
Journal Article
Closed access
PDF file
WKWeng Hua Khoo
Weng Hua Khoo
GLGuy Ledergor
Guy Ledergor
AWAssaf Weiner
Assaf Weiner
DRDaniel L. Roden
Daniel L. Roden
Rachael Louise TerryRachael Louise Terry
Rachael Louise Terry
PCPeter I. Croucher
Peter I. Croucher
The era of targeted therapies has seen significant improvements in depth of response, progression-free survival, and overall survival for patients with multiple myeloma. Despite these improvements in clinical outcome, patients inevitably relapse and require further treatment. Drug-resistant dormant myeloma cells that reside in specific niches within the skeleton are considered a basis of disease relapse but remain elusive and difficult to study. Here, we developed a method to sequence the transcriptome of individual dormant myeloma cells from the bones of tumor-bearing mice. Our analyses show that dormant myeloma cells express a distinct transcriptome signature enriched for immune genes and, unexpectedly, genes associated with myeloid cell differentiation. These genes were switched on by coculture with osteoblastic cells. Targeting AXL, a gene highly expressed by dormant cells, using small-molecule inhibitors released cells from dormancy and promoted their proliferation. Analysis of the expression of AXL and coregulated genes in human cohorts showed that healthy human controls and patients with monoclonal gammopathy of uncertain significance expressed higher levels of the dormancy signature genes than patients with multiple myeloma. Furthermore, in patients with multiple myeloma, the expression of this myeloid transcriptome signature translated into a twofold increase in overall survival, indicating that this dormancy signature may be a marker of disease progression. Thus, engagement of myeloma cells with the osteoblastic niche induces expression of a suite of myeloid genes that predicts disease progression and that comprises potential drug targets to eradicate dormant myeloma cells.

1 July 2016 in Cancer Letters
Verified
Journal Article
Closed access
KVKim De Veirman
Kim De Veirman
JWJinheng Wang
Jinheng Wang
SXSong Xu
Song Xu
XLXavier Leleu
Xavier Leleu
EHEddy Himpe
Eddy Himpe
IRIvan Van Riet
Ivan Van Riet

22 February 2018 in Leukemia
Verified
Journal Article
Open access
PDF file
SXSong Xu
Song Xu
KVKim De Veirman
Kim De Veirman
ABAnn De Becker
Ann De Becker
KVKarin Vanderkerken
Karin Vanderkerken
IRIvan Van Riet
Ivan Van Riet
Multiple myeloma (MM) is a malignant plasma cell (PC) disorder, characterized by a complex interactive network of tumour cells and the bone marrow (BM) stromal microenvironment, contributing to MM cell survival, proliferation and chemoresistance. Mesenchymal stem cells (MSCs) represent the predominant stem cell population of the bone marrow stroma, capable of differentiating into multiple cell lineages, including fibroblasts, adipocytes, chondrocytes and osteoblasts. MSCs can migrate towards primary tumours and metastatic sites, implying that these cells might modulate tumour growth and metastasis. However, this issue remains controversial and is not well understood. Interestingly, several recent studies have shown functional abnormalities of MM patient-derived MSCs indicating that MSCs are not just by-standers in the BM microenvironment but rather active players in the pathophysiology of this disease. It appears that the complex interaction of MSCs and MM cells is critical for MM development and disease outcome. This review will focus on the current understanding of the biological role of MSCs in MM as well as the potential utility of MSC-based therapies in this malignancy.